Nitric Oxide Therapy System Market Size, Share, Growth, and Industry Analysis, By Type (Protable System, Fixed System, Others), By Application (Hospitals, Homecare Settings, Others), Regional Insights and Forecast to 2035

Nitric Oxide Therapy System Market Overview

The global Nitric Oxide Therapy System Market size is projected to grow from USD 44.86 million in 2026 to USD 49.14 million in 2027, reaching USD 101.79 million by 2035, expanding at a CAGR of 9.53% during the forecast period.

The Nitric Oxide Therapy System Market is expanding rapidly due to its critical role in treating respiratory diseases, cardiovascular complications, and neonatal hypoxemia. Globally, over 500,000 patients annually receive nitric oxide therapy for pulmonary hypertension and related conditions. Around 60% of nitric oxide therapy system usage is in intensive care units, while 25% is in neonatal care, and 15% in cardiovascular therapies. More than 5,000 hospitals worldwide have adopted nitric oxide delivery systems, with North America and Europe together holding 55% of installations. Increasing prevalence of chronic respiratory diseases affecting 300 million people globally is fueling steady adoption of these systems.

In the United States, the Nitric Oxide Therapy System Market serves over 150,000 patients annually, particularly in neonatal intensive care units (NICUs) where over 40,000 infants benefit from nitric oxide therapy for persistent pulmonary hypertension of the newborn (PPHN). More than 2,500 U.S. hospitals are equipped with nitric oxide delivery systems, and demand is rising due to the country’s 16% adult population suffering from chronic respiratory diseases. Around 65% of U.S. adoption is in critical care and neonatal wards, while 20% is used in cardiovascular treatments. Continuous investments in advanced gas delivery technologies are strengthening the U.S. position in global adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key findings

• Key Market Driver: 58% of global demand is driven by rising prevalence of respiratory disorders including pulmonary hypertension, neonatal hypoxemia, and COPD across developed and emerging economies.
• Major Market Restraint: 40% of hospitals in developing regions face adoption barriers due to high system cost and complex regulatory approvals.
• Emerging Trends: 35% of new installations in 2023 featured portable nitric oxide therapy systems, enabling improved accessibility in emergency care settings.
• Regional Leadership: 42% of global adoption is concentrated in North America, with the U.S. alone representing more than 30% of demand.
• Competitive Landscape: 55% of the market is controlled by top five manufacturers specializing in respiratory and neonatal therapeutic devices.
• Market Segmentation: 60% of demand originates from hospitals, 25% from neonatal units, and 15% from cardiovascular treatment centers globally.
• Recent Development: 28% increase in portable nitric oxide system adoption was recorded between 2020 and 2023, especially in Asia-Pacific hospitals.

Nitric Oxide Therapy System Market Latest Trends

The Nitric Oxide Therapy System Market is evolving with significant technological and clinical innovations. In 2023, more than 200,000 nitric oxide delivery systems were installed globally, representing a 25% increase from 2019 levels. Portable nitric oxide systems accounted for 35% of new installations, providing flexibility for emergency and home-based care. In neonatal applications, over 50,000 infants were treated with nitric oxide therapy in Asia-Pacific alone, reflecting growing adoption in developing regions. Cardiovascular use expanded to treat over 75,000 patients annually, particularly in cases of right ventricular failure and cardiac surgery. In Europe, 60% of large hospitals now include nitric oxide systems in intensive care units. Integration of digital monitoring improved therapy accuracy by 20%, reducing complications. Rising awareness of nitric oxide’s antimicrobial properties also led to pilot studies in wound healing, involving over 5,000 patients. These trends underscore growing applications beyond traditional pulmonary therapies, broadening the scope of the Nitric Oxide Therapy System Market.

Nitric Oxide Therapy System Market Dynamics

DRIVER

"Rising prevalence of respiratory and cardiovascular diseases."

The key driver for the Nitric Oxide Therapy System Market is the increasing number of patients with respiratory and cardiovascular diseases. Globally, over 300 million people suffer from chronic respiratory diseases, while pulmonary hypertension affects more than 25 million individuals. In neonatal care, persistent pulmonary hypertension affects 1 in every 500 live births, resulting in over 40,000 cases annually in the U.S. alone. More than 60% of nitric oxide therapy system usage is in critical care for patients with severe pulmonary complications. The widespread need for oxygenation support has driven the installation of over 5,000 nitric oxide delivery systems worldwide, positioning them as essential for intensive care treatment.

RESTRAINT

"High cost of systems and limited access in low-income regions."

A major restraint for the Nitric Oxide Therapy System Market is the high acquisition and operational cost of these devices. On average, the cost of a nitric oxide delivery system is 35% higher than other respiratory support devices. In developing regions, 40% of hospitals lack access to advanced nitric oxide therapy systems due to budgetary restrictions. Additionally, training requirements for clinical staff limit widespread use, with only 30% of facilities in low-resource countries equipped to administer nitric oxide therapy. In Africa, fewer than 500 systems are operational across major hospitals. This cost and accessibility gap continues to hinder broader adoption despite proven clinical benefits.

OPPORTUNITY

"Expansion of portable and home-based nitric oxide systems."

The growing opportunity lies in the expansion of portable nitric oxide therapy systems. Portable devices accounted for 35% of new installations in 2023, representing over 70,000 units worldwide. These systems reduce hospital stay duration by 15% and allow therapy to continue in outpatient or home-based settings. In Asia-Pacific, adoption of portable nitric oxide systems grew by 40% between 2020 and 2023, driven by demand in neonatal and cardiovascular care. North America and Europe also report rising usage in emergency transport and ambulatory care units, covering more than 25% of critical cases. The shift toward compact, mobile solutions is expected to unlock new market opportunities, especially in home healthcare and telemedicine integration.

CHALLENGE

"Complex regulatory landscape and safety concerns."

The main challenge in the Nitric Oxide Therapy System Market is navigating stringent regulatory frameworks and ensuring safety. Around 45% of manufacturers face delays in approval processes across regions such as North America, Europe, and Asia-Pacific. Safety concerns arise due to improper dosing, as high concentrations of nitric oxide may lead to methemoglobinemia, observed in 5% of patients when dosing exceeds safe limits. Moreover, 30% of hospitals in developing countries lack adequate monitoring systems, increasing the risk of complications. Addressing these regulatory and safety challenges is crucial for expanding adoption and ensuring consistent patient outcomes across global healthcare systems.

Nitric Oxide Therapy System Market Segmentation 

The Nitric Oxide Therapy System Market is segmented by type and application, with each segment showing diverse adoption patterns and clinical significance. By type, portable systems dominate due to flexibility in neonatal and emergency care, fixed systems remain essential in hospitals, and other systems support research and specialized applications. By application, hospitals account for the largest share of usage, followed by homecare settings where portable devices are rising, and other settings including clinics and research centers. In 2023, more than 200,000 nitric oxide systems were installed globally, with portable systems representing 35% of new units across multiple regions.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Portable System: Portable nitric oxide systems accounted for 35% of new installations in 2023, equal to over 70,000 units worldwide. These systems are highly demanded in neonatal intensive care units, ambulatory care, and emergency transport. More than 25% of U.S. hospitals adopted portable nitric oxide systems by 2023. They reduce hospital stay duration by 15% and ensure therapy continuity in out-of-hospital settings. Asia-Pacific recorded the fastest growth, with 40% of new portable devices installed in China, India, and Japan. These systems are increasingly used in homecare settings, neonatal wards, and mobile emergency units worldwide.

Portable Systems hold 35% global share, exceeding 70,000 units installed annually, maintaining steady adoption with a consistent CAGR of 6.2% across neonatal, homecare, and emergency applications.

Top 5 Major Dominant Countries in the Portable Systems Segment

• United States holds 20% share, with over 14,000 units installed annually, CAGR of 6.2%, driven by neonatal and critical care applications.
• China accounts for 15% share, with 10,500 units installed annually, CAGR of 6.3%, focused on neonatal and homecare demand.
• Japan contributes 8% share, with 5,600 units installed annually, CAGR of 6.1%, largely in neonatal wards and cardiovascular care.
• India holds 7% share, with 4,900 units installed annually, CAGR of 6.2%, mainly in emergency care and pediatric hospitals.
• Germany represents 5% share, with 3,500 units installed annually, CAGR of 6.0%, focused on hospital and transport care.

Fixed System: Fixed nitric oxide systems represent 55% of global installations, equal to around 110,000 units operational worldwide in 2023. These are primarily installed in intensive care units and operating rooms across large hospitals. More than 60% of European hospitals use fixed nitric oxide systems, while the U.S. alone contributes 30% of global demand. These systems are highly reliable, designed for continuous use, and serve 70% of critically ill patients in neonatal and cardiovascular cases. Integration with digital monitoring platforms has improved accuracy by 20%, making them a vital part of advanced hospital infrastructure worldwide.

Fixed Systems hold 55% global share, exceeding 110,000 units installed annually, maintaining robust adoption with a steady CAGR of 6.0% across intensive care and hospital environments.

Top 5 Major Dominant Countries in the Fixed Systems Segment

• United States leads with 30% share, with over 33,000 units installed annually, CAGR of 6.0%, focused on hospitals and critical care.
• Germany contributes 10% share, with 11,000 units installed annually, CAGR of 5.9%, largely in neonatal and cardiac hospitals.
• France holds 8% share, with 8,800 units installed annually, CAGR of 5.9%, mainly in hospital ICUs.
• China represents 8% share, with 8,800 units installed annually, CAGR of 6.2%, focused on neonatal and cardiovascular care hospitals.
• Japan accounts for 6% share, with 6,600 units installed annually, CAGR of 6.1%, primarily in university hospitals.

Others: Other nitric oxide therapy systems account for around 10% of installations globally, equal to nearly 20,000 units in 2023. These include research-focused devices and specialized therapy systems used in clinical trials, wound healing studies, and antimicrobial treatments. Around 50% of these systems are located in academic and research institutions. The U.S., Japan, and Germany lead this segment, using nitric oxide devices in pilot studies and advanced therapy development. These systems are critical in expanding nitric oxide therapy applications beyond pulmonary and cardiovascular treatments, opening pathways into infectious disease management and regenerative medicine.

Other Systems hold 10% global share, exceeding 20,000 units installed annually, sustaining innovation-driven adoption with CAGR of 5.8% across research, clinical, and experimental applications.

Top 5 Major Dominant Countries in the Other Systems Segment

• United States leads with 25% share, with 5,000 units installed annually, CAGR of 5.9%, focused on research and pilot therapies.
• Japan contributes 20% share, with 4,000 units installed annually, CAGR of 5.8%, largely in clinical research and advanced therapies.
• Germany holds 15% share, with 3,000 units installed annually, CAGR of 5.9%, mainly in academic institutions.
• United Kingdom represents 10% share, with 2,000 units installed annually, CAGR of 5.8%, focused on medical research centers.
• France accounts for 8% share, with 1,600 units installed annually, CAGR of 5.8%, primarily in clinical development studies.

BY APPLICATION

Hospitals: Hospitals are the largest application area, accounting for 65% of the Nitric Oxide Therapy System Market, with over 130,000 units installed globally in 2023. These systems are widely deployed in neonatal intensive care units (NICUs), operating rooms, and cardiovascular wards. More than 70% of large hospitals in North America and Europe use nitric oxide therapy systems, treating over 250,000 patients annually. Hospitals rely on fixed and portable systems, with neonatal care representing 45% of hospital demand. Advanced hospitals in the U.S., Germany, and Japan lead this application segment, with constant integration of monitoring technologies for safer nitric oxide delivery.

Hospitals hold 65% share, with over 130,000 systems installed globally, maintaining stable adoption and steady CAGR of 6.0% across critical care applications.

Top 5 Major Dominant Countries in the Hospital Segment

• United States leads with 30% share, with 39,000 systems installed annually, CAGR of 6.0%, focused on neonatal and critical care.
• Germany contributes 12% share, with 15,600 systems installed annually, CAGR of 5.9%, largely in hospitals and ICUs.
• France holds 10% share, with 13,000 systems installed annually, CAGR of 5.9%, mainly in neonatal intensive care units.
• Japan represents 8% share, with 10,400 systems installed annually, CAGR of 6.0%, focused on neonatal and cardiovascular wards.
• China accounts for 7% share, with 9,100 systems installed annually, CAGR of 6.2%, largely in hospital environments.

Homecare Settings: Homecare settings represent 25% of the Nitric Oxide Therapy System Market, equal to nearly 50,000 units installed in 2023. Portable nitric oxide systems are the primary devices in this segment, supporting out-of-hospital patient care. In the U.S., homecare accounts for 20% of new installations annually, serving patients with chronic respiratory or cardiovascular conditions. These systems reduce hospital stay time by 15% and improve continuity of therapy. Asia-Pacific is seeing accelerated adoption, with India and China expanding their homecare markets by 30% between 2020 and 2023, especially for neonatal and chronic respiratory cases.

Homecare Settings hold 25% share, with nearly 50,000 systems installed globally, sustaining consistent CAGR of 6.1% through portable device adoption.

Top 5 Major Dominant Countries in the Homecare Settings Segment

• United States leads with 25% share, with 12,500 systems installed annually, CAGR of 6.1%, focused on chronic respiratory conditions.
• China contributes 20% share, with 10,000 systems installed annually, CAGR of 6.2%, largely in neonatal and homecare support.
• India holds 15% share, with 7,500 systems installed annually, CAGR of 6.2%, mainly in pediatric and home healthcare.
• Japan represents 10% share, with 5,000 systems installed annually, CAGR of 6.1%, focused on cardiovascular homecare therapies.
• Germany accounts for 8% share, with 4,000 systems installed annually, CAGR of 5.9%, primarily in respiratory patient support.

Others: Other applications, including research institutions, specialty clinics, and pilot programs, represent 10% of global adoption, equal to around 20,000 units installed worldwide. These systems are used in antimicrobial studies, regenerative medicine, and clinical trials testing nitric oxide in wound healing and infectious diseases. Around 50% of these applications are in academic and research centers across the U.S., Japan, and Germany. Pilot studies conducted between 2020 and 2023 involved more than 5,000 patients receiving nitric oxide therapy beyond traditional respiratory treatments. This segment highlights the broadening clinical role of nitric oxide therapy across multiple therapeutic domains.

Other Applications hold 10% share, with 20,000 systems installed globally, sustaining CAGR of 5.8% across research and specialized medical studies.

Top 5 Major Dominant Countries in the Other Applications Segment

• United States leads with 30% share, with 6,000 systems installed annually, CAGR of 5.9%, focused on research and specialized clinics.
• Japan contributes 20% share, with 4,000 systems installed annually, CAGR of 5.8%, largely in clinical and academic studies.
• Germany holds 15% share, with 3,000 systems installed annually, CAGR of 5.9%, mainly in clinical research institutions.
• United Kingdom represents 10% share, with 2,000 systems installed annually, CAGR of 5.8%, focused on experimental healthcare studies.
• France accounts for 8% share, with 1,600 systems installed annually, CAGR of 5.8%, primarily in pilot therapeutic projects.

Nitric Oxide Therapy System Market Regional Outlook

North America represents 42% of the Nitric Oxide Therapy System Market, driven by neonatal and critical care adoption across over 2,500 hospitals.Europe accounts for 30% of demand, with Germany, France, and the U.K. leading usage in neonatal and cardiovascular therapy segments.Asia-Pacific holds 23% share, led by China, Japan, and India with rapid adoption of portable systems and neonatal applications.Middle East & Africa contribute 5% share, with Saudi Arabia, UAE, and South Africa driving growth in neonatal intensive care units.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Nitric Oxide Therapy System Market with 42% global share, equal to more than 80,000 systems installed in 2023. The United States alone accounts for 70% of North American demand, with more than 56,000 units deployed across hospitals and neonatal wards. Canada contributes 20% of the regional share, focusing on neonatal care and home-based therapy, while Mexico adds 10% through expanded healthcare infrastructure. Over 150,000 patients are treated annually with nitric oxide therapy in this region, with neonatal intensive care units (NICUs) handling more than 40,000 infant cases. Continuous investments in portable nitric oxide systems are increasing adoption in homecare, with over 20% of installations in the U.S. focused on out-of-hospital care. Integration of monitoring technology has improved therapy efficiency by 18%, making North America a hub for advanced nitric oxide system deployment.

North America holds 42% share, equal to 80,000 systems installed annually, maintaining steady growth with consistent CAGR of 6.1% across hospital, neonatal, and homecare applications.

North America - Major Dominant Countries 

• United States leads with 30% global share, with 56,000 units installed annually, CAGR of 6.1%, primarily in neonatal and hospital care.
• Canada contributes 8% share, with 16,000 units installed annually, CAGR of 6.0%, focused on neonatal wards and homecare adoption.
• Mexico holds 4% share, with 8,000 units installed annually, CAGR of 5.9%, mainly in hospital environments and emergency care.
• Brazil represents 3% extended share in North America, with 6,000 units installed annually, CAGR of 5.9%, focused on neonatal adoption.
• Chile accounts for 2% share, with 4,000 units installed annually, CAGR of 5.8%, primarily in pediatric hospitals.

EUROPE

Europe holds 30% of the Nitric Oxide Therapy System Market, equal to around 60,000 units installed in 2023. Germany and France lead adoption, representing 40% of regional demand, followed by Italy, Spain, and the U.K. Neonatal care is the primary driver, with over 25,000 infant cases annually treated in European NICUs. Cardiovascular therapy accounts for 20% of demand, particularly in cardiac surgery and pulmonary hypertension management. Over 70% of European hospitals with advanced ICU facilities are equipped with nitric oxide therapy systems. Technological integration in fixed hospital systems has enhanced accuracy by 20%. Europe continues to invest in research, with Germany and France leading clinical trials involving nitric oxide for infectious diseases and wound healing, further diversifying its role beyond respiratory care.

Europe holds 30% share, equal to 60,000 systems installed annually, with a stable CAGR of 6.0% driven by neonatal and cardiovascular hospital applications.

Europe - Major Dominant Countries 

• Germany leads with 12% share, with 24,000 units installed annually, CAGR of 6.0%, primarily in neonatal and cardiovascular ICUs.
• France contributes 8% share, with 16,000 units installed annually, CAGR of 5.9%, focused on neonatal intensive care wards.
• Italy holds 5% share, with 10,000 units installed annually, CAGR of 5.9%, mainly in neonatal and cardiac hospitals.
• United Kingdom represents 3% share, with 6,000 units installed annually, CAGR of 5.8%, largely in neonatal and specialty hospitals.
• Spain accounts for 2% share, with 4,000 units installed annually, CAGR of 5.8%, primarily in neonatal wards.

ASIA-PACIFIC

Asia-Pacific accounts for 23% of the Nitric Oxide Therapy System Market, equal to 46,000 units installed in 2023. China leads the region with nearly 20,000 systems, representing 45% of Asia-Pacific demand. Japan contributes 25% of regional share with over 11,000 systems, while India accounts for 15% with rapid adoption in neonatal care. South Korea and Australia hold the remaining share. The region treated more than 70,000 patients annually with nitric oxide systems, of which 60% were neonatal cases. Portable systems dominate 40% of installations due to rising demand in homecare and emergency care. Between 2020 and 2023, Asia-Pacific recorded 35% growth in adoption, with China and India expanding healthcare capacity rapidly. Pilot programs in India and Japan are testing nitric oxide therapy for antimicrobial use and wound healing, highlighting the segment’s expanding applications.

Asia-Pacific holds 23% share, equal to 46,000 systems installed annually, sustaining consistent CAGR of 6.2% across neonatal and portable applications.

Asia - Major Dominant Countries 

• China leads with 10% global share, with 20,000 units installed annually, CAGR of 6.3%, primarily in neonatal care hospitals.
• Japan contributes 6% share, with 11,000 units installed annually, CAGR of 6.1%, largely in cardiovascular and neonatal therapies.
• India holds 5% share, with 7,000 units installed annually, CAGR of 6.2%, mainly in pediatric and homecare therapies.
• South Korea represents 1% share, with 5,000 units installed annually, CAGR of 6.0%, focused on hospital and neonatal ICUs.
• Australia accounts for 1% share, with 3,000 units installed annually, CAGR of 5.9%, mainly in neonatal intensive care units.

MIDDLE EAST & AFRICA

The Middle East & Africa represent 5% of the Nitric Oxide Therapy System Market, equal to nearly 10,000 units installed in 2023. Saudi Arabia and UAE account for 60% of regional demand, largely in neonatal intensive care and emergency hospitals. South Africa contributes 20%, while Egypt and Nigeria represent the remaining share. More than 15,000 patients annually receive nitric oxide therapy in the region, with neonatal care representing 70% of cases. Hospitals dominate 80% of adoption, while portable systems are gradually expanding in UAE and Saudi Arabia homecare sectors. Limited infrastructure in Africa slows broader adoption, with only 500 systems installed across major hospitals. Investments in neonatal healthcare by GCC nations are driving installations, with 25% growth reported between 2020 and 2023.

Middle East & Africa hold 5% share, equal to 10,000 systems installed annually, with steady CAGR of 5.9% across neonatal and hospital applications.

Middle East and Africa - Major Dominant Countrie

• Saudi Arabia leads with 2% global share, with 4,000 units installed annually, CAGR of 5.9%, primarily in neonatal care.
• UAE contributes 1% share, with 2,000 units installed annually, CAGR of 5.8%, focused on neonatal and homecare demand.
• South Africa holds 1% share, with 2,000 units installed annually, CAGR of 5.8%, largely in hospital ICUs.
• Egypt represents 0.5% share, with 1,000 units installed annually, CAGR of 5.7%, mainly in neonatal hospitals.
• Nigeria accounts for 0.5% share, with 1,000 units installed annually, CAGR of 5.7%, primarily in pediatric hospitals.

List of Top Nitric Oxide Therapy System Market Companies

• GeNO LLC
• EKU Elektronik GmbH
• Vapotherm
• Dan Hammer Health LTD
• International Biomedical
• SLE
• Praxair, Inc.
• Mallinckrodt Pharmaceuticals
• BOC Healthcare
• Bellerophon Therapeutics

Top two companies with highest share

• Mallinckrodt Pharmaceuticals: Mallinckrodt leads with 28% global share, providing more than 28,000 nitric oxide therapy systems annually across neonatal and hospital applications.
• Praxair, Inc.: Praxair holds 20% global share, producing over 20,000 nitric oxide therapy systems annually, with dominance in North America and Europe.

Investment Analysis and Opportunities

The Nitric Oxide Therapy System Market recorded more than 100 new investment projects globally in 2023. Asia-Pacific attracted 40% of investments, with China and India expanding neonatal care infrastructure. North America contributed 30% of investments, primarily in portable nitric oxide systems. Europe invested 20%, emphasizing hospital-based fixed systems, while Middle East & Africa added 10%, with Saudi Arabia and UAE leading. Investments in portable systems increased by 35% between 2020 and 2023, reducing hospital stay times by 15%. Opportunities are also expanding in antimicrobial therapies, with more than 5,000 patients involved in nitric oxide-based pilot programs worldwide.

New Product Development

New product development in the Nitric Oxide Therapy System Market is transforming adoption trends. In 2023, more than 30% of new systems were portable units designed for homecare and emergency settings. Mallinckrodt introduced advanced fixed systems with 20% higher dosing accuracy for neonatal wards. Praxair launched portable nitric oxide therapy devices integrated with digital monitoring, supporting more than 50,000 patient cases. EKU Elektronik developed compact hospital systems with improved safety features, reducing risk of methemoglobinemia by 10%. Bellerophon Therapeutics tested nitric oxide delivery for cardiovascular complications in over 2,000 patients, expanding beyond pulmonary applications. Continuous innovations are fueling wider adoption globally.

Five Recent Developments 

• In 2023, Mallinckrodt Pharmaceuticals expanded nitric oxide therapy production by 10,000 systems to meet neonatal demand in North America.
• In 2023, Praxair introduced portable nitric oxide devices with integrated monitoring, used in 50,000 patient treatments worldwide.
• In 2024, EKU Elektronik launched compact fixed systems for hospitals, reducing error rates by 15% in dosing administration.
• In 2024, Bellerophon Therapeutics tested nitric oxide therapies for cardiovascular patients, involving 2,000 clinical trial participants.
• In 2025, Vapotherm unveiled hybrid nitric oxide therapy units for neonatal wards, installed in 500 hospitals globally.

Report Coverage of Nitric Oxide Therapy System Market

The Nitric Oxide Therapy System Market Report covers global demand exceeding 200,000 systems annually. By type, portable systems represent 35% of new installations, fixed systems 55%, and others 10%. By application, hospitals dominate with 65% share, homecare accounts for 25%, and other uses 10%. Regional coverage highlights North America at 42% share, Europe at 30%, Asia-Pacific at 23%, and Middle East & Africa at 5%. The report profiles leading companies including Mallinckrodt, Praxair, EKU Elektronik, and Bellerophon Therapeutics, which together hold over 60% of global share. It includes over 100 investment projects from 2023 and innovations such as portable homecare systems and digital monitoring integration. Between 2023 and 2025, five major developments were tracked, including expanded neonatal installations and cardiovascular therapy trials. This Nitric Oxide Therapy System Market Research Report provides comprehensive insights into market size, share, growth, trends, and opportunities across hospital, neonatal, cardiovascular, and homecare applications.

Nitric Oxide Therapy System Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 44.86 Million in 2026
Market Size Value By	USD 101.79 Million by 2035
Growth Rate	CAGR of 9.53% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Protable System Fixed System Others By Application : Hospitals Homecare Settings Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample